In light of this, several ongoing multicenter randomized controlled trials (e.g., NCT06018493 and NCT06283758 for primary hypertension, as well as NCT06225723 for metabolic associated fatty liver disease) will further evaluate the efficacy and safety of this modification approach directly targeting PRAT in metabolic diseases. Here, PPAT is linked to essential hypertension.